We give you a written timeline estimate for your case before you commit.Ask about treatment
Kawasaki disease: US-approved treatments and how families in the Gulf can access them
A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Kawasaki disease: the short answer
The US FDA has approved one medicine covered on this page for Kawasaki disease, each for a specific group of patients: Gammagard S/D. On 17 October 2026, none of them was on the Saudi or Abu Dhabi register we checked. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Gammagard S/D.
- Gulf registers (checked 17 October 2026): see each medicine below.
- Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is Kawasaki disease?
Kawasaki disease is a rare illness that usually affects small children. It is a type of vasculitis, which means the blood vessels become inflamed. It happens when the immune system injures the blood vessels by mistake, and researchers do not fully know why. It does not seem to be contagious.[1]
It usually affects children under age 5 and is more common in boys. It often begins with a fever of 38.9 C (102 F) or higher that does not go away, lasting at least 5 days, with red eyes, red cracked lips, a strawberry tongue, rash and swollen hands and feet.[1, 2]
Kawasaki disease can damage the coronary arteries of the heart. It is usually treated in hospital with intravenous immunoglobulin (IVIG), and aspirin may also be part of treatment. Most children recover fully if treated right away.[1, 3]
Kawasaki disease in the Gulf
Kawasaki disease has been described across the Gulf, including a single-institution study of its epidemiology and incomplete form in the United Arab Emirates (2023), a clinical study from Oman (2003), a study from western Saudi Arabia (2010), and a Middle Eastern cohort comparing it with MIS-C (2023).[4, 5, 6, 7]
We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 0 of 1 were listed in Saudi Arabia and 0 of 1 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[8, 9]
US FDA-approved medicines for Kawasaki disease
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Gammagard S/D (immune globulin intravenous (human))
US FDA-approved for prevention of coronary artery aneurysms associated with Kawasaki syndrome in children, among other uses such as primary immunodeficiency. It is an immune globulin given into a vein in hospital.[3]
Current US label version: 25 November 2025. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): not found. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[8, 9]
How families in the Gulf can access treatment
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[10, 11] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
- Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for Kawasaki disease
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for Kawasaki disease?
Yes. The medicine on this page has US FDA approval for specific groups of patients: Gammagard S/D. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Gammagard S/D available in Saudi Arabia or the UAE?
We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (Department of Health drug code list): not found. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.
How can a family in the Gulf get Gammagard S/D?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Does Reserve Meds diagnose or prescribe?
No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.
Why is IVIG given quickly in Kawasaki disease?
Prompt treatment with intravenous immunoglobulin lowers the risk of damage to the heart's coronary arteries. Hospitals in the Gulf usually stock IVIG products, so treatment should not wait for an import.
Sources for the condition-specific answers: [1, 3]
Sources
Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.
- MedlinePlus (US National Library of Medicine): Kawasaki Disease
- MedlinePlus (US National Library of Medicine): Kawasaki disease
- DailyMed: GAMMAGARD S/D (immune globulin intravenous (human)) US prescribing information, label version 25 November 2025
- Al Zubaidi A, et al. Epidemiology of Kawasaki Disease, Its Incomplete Form and Outcomes: A Single-Institution Experience in the United Arab Emirates. Cureus. 2023 (PubMed 38288209)
- Bhatnagar SK, et al. Kawasaki disease in Oman--a clinical study. J Trop Pediatr. 2003 (PubMed 14725413)
- Al-Harbi KM, et al. Kawasaki disease in Western Saudi Arabia. Saudi Med J. 2010 (PubMed 21063651)
- Yavuz L, et al. Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) in a Middle Eastern patient cohort. Pediatr Rheumatol Online J. 2023 (PubMed 37386568)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- ANCA-associated vasculitis
- Giant cell arteritis
- Named-patient access in the Gulf, explained
- US-approved medicines not yet registered in the Gulf
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
This page is general health information, not medical advice. It does not replace a consultation with your doctor.